At its meeting on 8 May 2023, the Transparency Council adopted Position No. 49/2023 on the evaluation of the drug Tresiba (insulin degludec) for the indication for the treatment of type 1 and type 2 diabetes.
At its meeting on 8 May 2023, the Transparency Council adopted Position No. 49/2023 on the evaluation of the drug Tresiba (insulin degludec) for the indication for the treatment of type 1 and type 2 diabetes.